SGHT vs. MDXG, SIBN, IRMD, CBLL, BBNX, AVNS, EMBC, BVS, KIDS, and RXST
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include MiMedx Group (MDXG), SiBone (SIBN), iRadimed (IRMD), CeriBell (CBLL), Beta Bionics (BBNX), Avanos Medical (AVNS), Embecta (EMBC), Bioventus (BVS), OrthoPediatrics (KIDS), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
Sight Sciences vs. Its Competitors
MiMedx Group (NASDAQ:MDXG) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.
MiMedx Group has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
MiMedx Group has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500.
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by insiders. Comparatively, 30.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Sight Sciences had 10 more articles in the media than MiMedx Group. MarketBeat recorded 12 mentions for Sight Sciences and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.52 beat Sight Sciences' score of 0.51 indicating that MiMedx Group is being referred to more favorably in the media.
MiMedx Group currently has a consensus target price of $12.50, suggesting a potential upside of 87.69%. Sight Sciences has a consensus target price of $4.10, suggesting a potential upside of 20.23%. Given MiMedx Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe MiMedx Group is more favorable than Sight Sciences.
MiMedx Group has a net margin of 11.40% compared to Sight Sciences' net margin of -63.24%. MiMedx Group's return on equity of 22.70% beat Sight Sciences' return on equity.
Summary
MiMedx Group beats Sight Sciences on 12 of the 15 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 7/12/2025 by MarketBeat.com Staff
